Abstract:Allergic diseases, affecting millions worldwide, have shown a progressive increase in recent years. Existing anti-allergy drugs primarily target symptoms and downstream reactions, necessitating the exploration of novel therapeutics addressing the root causes in the allergy pathway. Thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33), classified as upstream cytokines, play pivotal roles in initiating type-2 immunity and are implicated in allergic diseases. However, small molecule antagonists for both TSLP and IL-33 proteins are still in early development and not yet available as treatments for allergic diseases. This study focuses on identifying natural small molecules that can inhibit both TSLP and IL-33 proteins. The study employed structure-based virtual screening to identify potential dual inhibitors of TSLP and IL-33 from the ZINC database. Through the use of Autodock Vina in PyRx software, virtual screening was conducted to predict the binding mode and binding affinity of these compounds. Molecular dynamics simulations utilizing GROMACS and binding free energy calculations (MM/PBSA) were performed to evaluate the stability and strength of interactions between the identified compounds and the target proteins. Additionally, bioavailability and toxicity analyses were carried out to evaluate the safety and pharmacokinetic properties of the compounds. The study successfully pinpointed three promising compounds, namely ZINC01105767 and ZINC08764679 (fused heterocyclic compounds), and ZINC33833100 (a limonin analogue), as potential dual inhibitors of both TSLP and IL-33 proteins. Molecular dynamics simulations confirmed the structural stability of these complexes, and the analysis of RMSD, RMSF, Rg, and SASA indicated strong interactions. Furthermore, the bioavailability analysis revealed drug-like properties, and toxicity analysis suggested that the compounds are non-mutagenic and non-tumorigenic. ZINC01105767, ZINC08764679, and ZINC33833100 represent promising lead candidates for the treatment of allergic diseases, particularly being heterocyclic compounds with benzoxalyl coumarin, and chromone moieties, which have shown effectiveness in allergic disease treatment.The comprehensive computational analysis provides valuable insights into the structural stability, structural integrity, compactness, folding properties and safety profiles of these compounds, highlighting their potential as anti-allergy agents. Among three dual candidate inhibitors, based on the MM/PBSA based binding free energy analysis, ZINC01105767 emerged as the most promising dual inhibitor, demonstrating the strongest binding affinity with a binding free energy of −43.31 kcal/mol in case of TSLP and −29.87 kcal/mol in case of IL-33. This suggests a potent interaction with both TSLP and IL-33 proteins, indicating its potential as a dual inhibitor targeting these pathways simultaneously. This study paves the way for further investigations and experimental validations, ultimately contributing to the development of more effective therapies for allergic diseases.

Application of a New Heterocycles Compound on Allergic Rhinitis by Regulating Th17/Treg Immune Response

Identification of Some Promising Heterocycles Useful in Treatment of Allergic Rhinitis: Virtual Screening, Pharmacophore Mapping, Molecular Docking, and Molecular Dynamics

Assessment of Tumor Growth Factor-Β1 Neutralizing Antibody in the Treatment of Allergic Rhinitis and Asthma.

An Antagonist for CCR4 Alleviates Murine Allergic Rhinitis by Intranasal Administration

Exploration of Potential Targets and Molecular Mechanisms of the Yiqi Jianpi Tongqiao Formula in Treating Allergic Rhinitis Mouse Model based on Network Pharmacology and Molecular Docking

Aureane-type sesquiterpene tetraketides as a novel class of immunomodulators with interleukin-17A inhibitory activity

Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.

Discovery of Potent Antiallergic Agents Based on an O-Aminopyridinyl Alkynyl Scaffold

Integrative analysis of network pharmacology and proteomics to identify key targets of Tuomin-Zhiti-Decoction for allergic rhinitis

Alleviation of Murine Allergic Rhinitis by C19, a C-terminal Peptide of Chemokine-Like Factor 1 (CKLF1)

Integrative Analysis of Systems Pharmacology and Proteomics to Identify Key Targets and Pathways of Tuomin-Zhiti-Decoction for Allergic Rhinitis

Design, Synthesis and Biological Activities of A Series of Piperazine Pyrimidine As Ccr4 Antagonists

“Relative Symmetry with Electronegativity of Different Key-Groups” Strategy for MRGPRX2 Antagonist Design and Its Effect on Antigen-Induced Pulmonary Inflammation

Integration of bioinformatics analysis, molecular docking and animal experiments to study the therapeutic mechanisms of berberine against allergic rhinitis

Discovery of natural dual inhibitors from ZINC database targeting thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33) as potential anti-allergy agents

Design and synthesis of a series of pyrido[2,3-d]pyrimidine derivatives as CCR4 antagonists.

Design, Synthesis and Phenotypic Evaluation of N-Biaryl Amides for Il-17a Suppression

Pharmacophore Model-based Design and Synthesis of New Structure Small Molecule CCR2 Inhibitors

Screening of Prospective Plant Compounds As H1R and CL1R Inhibitors and Its Antiallergic Efficacy Through Molecular Docking Approach

Long-acting Anti-Inflammatory Injectable DEX-Gel with Sustained Release and Self-Healing Properties Regulates T H 1/T H 2 Immune Balance for Minimally Invasive Treatment of Allergic Rhinitis

Integration of network pharmacology and proteomics to elucidate the mechanism and targets of traditional Chinese medicine Biyuan Tongqiao granule against allergic rhinitis in an ovalbumin-induced mice model